CoChat

Treatment of Mycobacterium abscessus Pulmonary Disease

Griffith, David E., Daley, Charles L. · 2022 · CHEST
Cited by 190

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Mycobacterium abscessus is the second most common nontuberculous mycobacterial lung disease pathogen and comprises three subspecies, abscessus, massiliense and bolletii. Subspecies identification is critical for disease management as subspecies abscessus and bolletii have an inducible macrolide resistance gene (erm(41)) that results in clinical macrolide resistance. In contrast subspecies massiliense does not have an active erm(41) gene and is therefore susceptible in vitro and clinically to macrolide-containing regimens. M. abscessus is also vulnerable to acquired mutational macrolide resistance. Macrolide resistance has such a profoundly negative impact on M. abscessus treatment response that preserving macrolide susceptibility with adequate companion drugs for macrolides is among the highest treatment priorities. After macrolides, amikacin is regarded as the next most important drug for M. abscessus treatment, although data validating that assertion are lacking. The considerations for preventing acquired macrolide resistance also apply to amikacin. Recent guidelines suggest treatment should be guided by in vitro susceptibilities but aside from macrolide and amikacin, no other antibiotics have a validated minimum inhibitory concentration for M. abscessus. Currently, phase therapy (intensive and continuation) is recommended for M. abscessus. This approach is successful with macrolide susceptible M. abscessus but not with macrolide resistant M. abscessus where even more aggressive therapy is not predictably successful. Newer drugs have become available with encouraging in vitro activity against M. abscessus, but in vivo validation of their superiority to current agents is not yet available. In the absence of unequivocally effective regimens, we offer suggestions for managing this treatment refractory organism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chest.2021.07.035

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 190

Metadata

Authors
Griffith, D. E., & Daley, C. L.
Venue
CHEST
Publisher
Elsevier BV
Published
2022-01
Volume
161
Issue
1
Pages
64-75
ISSN
0012-3692 (ISSN-L)
OpenAlex
W3183755822
Cited by
190
References
1
FWCI
16.39
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Mycobacterium abscessus Pulmonary Disease. https://app.cochat.ai/papers/10.1016/j.chest.2021.07.035
The paper
Griffith, D. E., & Daley, C. L. (2022). Treatment of Mycobacterium abscessus Pulmonary Disease. CHEST. https://doi.org/10.1016/j.chest.2021.07.035

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.